Three months after New York schools implemented a bell-to-bell cell phone ban, the state is touting a transformative impact, citing more focused learning and more effective teaching, according to a ...

AI acts as an amplifier, magnifying existing organizational strengths and weaknesses, making culture and systems more visible. Jidoka, rooted in Toyota’s lean management, combines automation with ...

Here’s what you’ll learn when you read this story: With more than 100,000 people in need of an organ transplant in the U.S. alone, scientists have turned toward perfecting human-animal chimeras as a ...

All cells need to sense and respond to their environment, to know when to activate genes, build proteins, and carry out their basic functions. One of the most well-studied cellular responses is how ...

In this video, we explain the Work-Energy Principle and how to determine the work done on an object. Learn how force, displacement, and the angle between them come into play when calculating work, and ...

When I was in high school, my English teacher, Mr. Kaplow, started what he called a “casual dating club.” (Don’t laugh or report him — it was the 1990s!) This wasn’t about hookups or anything messy.

Oct 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.

Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the ...

Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi were awarded the prize for research showing how the body regulates its immune responses. By Gina Kolata and Ali Watkins Mary E. Brunkow, Fred ...

When you envision “the future of work,” you may picture a space-age setting with robots zipping around a silver-clad office. While pop culture might have ingrained this image in our heads, the reality ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Japanese pharma giant ...

Takeda is tapping out of the cell therapy arena as part of a "strategic portfolio reprioritization," with 137 roles at the drugmaker's Massachusetts R&D site affected. The company is seeking a partner ...